I don’t feel like this PR is related to CYDY and
Post# of 145190
![Avatar](/images/ProfileImages/573000060_60093_FD245EF6-37BD-4C88-9356-29519D0376AD.jpeg)
“The client is an early stage development company with a high potential early stage asset.” - CYDY is not an early stage company and leronlimab is not an early stage asset
“and will increase to $301 million US when the client obtains approval for the product.” - Isn’t the deal with $1 billion?
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)